ADTX: aditxt.com Company Value to Net Income
The current price chart for Aditxt (ADTX) helps assess the efficiency of the biotech platform, which combines IT diagnostics with the development of drugs for asset protection. Growth for Aditxt is driven by the implementation of the AditxtScore system and a personalized approach to health, with the indicator standing at 0.00. Despite patent protection and FDA requirements, a prolonged development cycle and financial volatility weaken the issuer's market position.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_ADTX_-_Aditxt_-_PE-Multiple "ADTX: Aditxt Corp Business Payback Period 07/04/2022 - 06/27/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Aditxt Inc. (ADTX)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
- earnings and market multiples details:
ADTX - Net Profit|Net Profit Forecast Aditxt|ADTX - P/E Multiple|Market Cap to Projected Earnings Aditxt Corp|ADTX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Aditxt, Inc.|ADTX - Operating profit before deduction of amortization|Earnings per share for the last 12 months Aditxt|ADTX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months aditxt.com|ADTX - Earnings growth in current year|Earnings growth forecast for next year Aditxt
Comprehensive company analysis:aditxt.com ADTX
For Aditxt (ADTX), the P/E ratio serves as a tool to compare the business's market value with its actual profitability. This metric determines the number of years required to recoup investments based on the current rate of net income generation. By analyzing the market valuation via P/E, an investor identifies cyclical price reversal points. High values here are justified by the implementation of the AditxtScore platform and expansion into the US B2B clinic segment. Cost optimization should transform this multiple into a signal of fundamental growth.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|AbCellera Bio - P/E Multiple|TRML - P/E Multiple|PGEN: P/E Multiple|Price to Earnings Multiple PHAR|NKTR (Nektar Therapeutics Inc.) - P/E Multiple|Upstream Bio, Inc. (UPB) - Business Payback Period|Price to Earnings Ratio ZBIO (Zenas Biopharma, Inc.)|Market Price to Net Income Ratio IMNM|Gossamer Bio, Inc. - Price to Earnings Ratio|KALV: Price to Earnings Multiple|SEPN: Price to Earnings Ratio|Pieris Pharma - Market Price to Net Income Ratio|SVRA: P/E Multiple|Rigel Corp (RIGL) - P/E Multiple|ANAB (AnaptysBio, Inc.) - P/E Multiple|Price to Earnings Multiple ATXS (astriatx.com)|Price to Earnings Ratio ENGN (enGene)|Market Price to Net Income Ratio RAPT|Aerovate Therapeutics - Price to Earnings Ratio|ACRS: Price to Earnings Multiple|KYTX - Price to Earnings Ratio|Market Cap to Net Income TLSA|CABA: P/E Multiple|Ventyx Biosciences Inc. - Company Value to Net Income|THTX (Theratechnologies Inc) - P/E Multiple|P/E Multiple Avalo Therapeutics Inc|Price to Earnings Ratio Eledon Pharmaceuticals (ELDN)|AGEN (agenusbio.com) - Company Value to Net Income|Price to Earnings Ratio Climb Bio CLYM|ZURA - Price to Earnings Ratio|aTyr - P/E Multiple|ADAG - P/E Multiple|IMA (ikenaoncology.com) - Price to Earnings Ratio|Shattuck Labs - Company Value to Net Income|EQ (Equillium Inc) - P/E Multiple|Connect Pharma (CNTB) - Business Payback Period|Price to Earnings Ratio Immunic, Inc. (IMUX)|Price to Earnings Ratio atarabio.com ATRA|Price to Earnings Ratio InflaRx IFRX|XFOR - Price to Earnings Ratio|ACET: Price to Earnings Ratio|CELU - P/E Multiple|INmune Bio Corp (INMB) - Price to Earnings Ratio|Price to Earnings Multiple BRNS|KZR (Kezar Life Sciences) - P/E Multiple|Market Cap to Earnings sabbiotherapeutics.com SABS|P/E Multiple AKTX|P/E Multiple enlivex.com (ENLV)|P/E Multiple QTTB (Q32 Bio)|GOVX: Price to Earnings Multiple|Edesa Biotech, Inc. - P/E Multiple|Business Payback Period ibioinc.com IBIO|CARM (carismatx.com) - Price to Earnings Ratio|XTLB: Market Price to Net Income Ratio|Price to Earnings Ratio BOLT|Price to Earnings Multiple HCWB (HCW Biologics Inc)|Price to Earnings Ratio APVO (Aptevo Therapeutics)|Market Price to Net Income Ratio AIM|P/E Multiple GRI (GRI Bio)|P/E Multiple XORTX Therapeutics Inc XRTX|ReShape Lifesciences - P/E Multiple|REVB (Revelation Biosciences Corp) - Price to Earnings Multiple|INDP (Indaptus Therapeutics) - Price to Earnings Ratio|SCNI: Market Price to Net Income Ratio|Price to Earnings Ratio CALI|Price to Earnings Multiple AFMD (Affimed Therapeutics)|Price to Earnings Ratio Allakos Inc. (ALLK)|HOOK: Market Cap to Net Income|P/E Multiple IGMS (IGM Biosciences)|Company Value to Net Income ITOS|Ocean Biomedical - P/E Multiple|TCBP - P/E Multiple|Third Harmonic Bio, Inc (THRD) - Price to Earnings Ratio
